Bifidobacterium longum NCIMB 42020 Modulates Immune Response to Respiratory Viruses
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for respiratory viral infections, such as those caused by influenza, rhinovirus, and RSV, often lead to excessive immunopathology and secondary bacterial infections due to Type I IFN responses, which can be detrimental, especially in susceptible individuals like those with COPD, asthma, or obesity, as they fail to effectively limit viral replication without inducing inflammatory damage.
Innovation Solution
The use of a specific strain of Bifidobacterium longum NCIMB 42020, which attenuates the IP-10 response, enhances Type III interferon lambda response, and suppresses Type I interferon alpha and beta responses, along with increasing surfactant protein D levels, to modulate the immune response and reduce inflammatory damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Type I interferon responses are activated to clear viral infection, then viral replication is limited, but excessive immunopathology and secondary bacterial infections occur
Solution Approach 1:
The patent introduces Type III interferons (IFN-λ) as an intermediary mechanism that provides antiviral protection without triggering the harmful Type I interferon cascade. IFN-λ acts as a mediator that limits viral replication while avoiding the excessive immunopathology and secondary bacterial infections associated with Type I interferon responses, particularly in susceptible individuals with COPD, asthma, or obesity
Solution Approach 2:
The patent changes the immunological parameter from Type I interferon response to Type III interferon response. This parameter change shifts the immune mechanism from one that effectively clears virus but causes harm to one that provides antiviral protection with reduced immunopathology, thereby resolving the contradiction between viral clearance efficacy and harmful side effects
2Object-generated harmful factors
If corticosteroids are administered to reduce inflammation, then immunopathology is decreased, but viral burden is not reduced and secondary bacterial infections are inhibited
Solution Approach 1:
The patent converts the harmful Type I interferon response into a beneficial Type III interferon response. Instead of using corticosteroids to suppress the harmful effects of Type I interferon, the invention utilizes IFN-λ to provide the antiviral benefits while inherently avoiding the harmful immunopathology, thus converting a harmful pathway into a beneficial one
Solution Approach 2:
Type III interferons serve as an intermediary that achieves the protective effects without requiring immunosuppression. IFN-λ provides antiviral activity and reduces immunopathology without the need for corticosteroid-mediated immunosuppression, thereby maintaining immune competence against secondary bacterial infections while still protecting against viral damage
Data Source
AI summary
An isolated strain of Bifidobacterium longum NCIMB 42020 is useful for the treatment of viral infections, especially viral respiratory infections such as influenza, rhinovirus and RSV. Bifidobacterium longum NCIMB 42020 is also useful for clearing secondary bacterial infections.